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Accepted 5 July 2018Objective: This systematic review and meta-analysis of randomized controlled trials (RCTs) was performed to
summarize the effect of alpha-lipoic acid (ALA) supplementation on glycemic control and lipid proﬁles among
patients with metabolic diseases.
Methods: We searched the following databases till October 2017: MEDLINE, EMBASE, Web of Science and
Cochrane Central Register of Controlled Trials. The relevant data were extracted and assessed for quality of the
studies according to the Cochrane risk of bias tool. Data were pooled using the inverse variance method and
expressed as standardized mean difference (SMD) with 95% conﬁdence intervals (95% CI). Heterogeneity be-
tween studieswas assessed by the CochranQ statistic and I-squared tests (I2). Twenty-four studieswere included
in the meta-analyses.
Results: The ﬁndings of thismeta-analysis showed that ALA supplementation among patientswithmetabolic dis-
eases signiﬁcantly decreased fasting glucose (SMD -0.54; 95% CI,−0.89, –0.19; P= 0.003), insulin (SMD –1.01;
95% CI, −1.70, −0.31; P = 0.006), homeostasis model assessment of insulin resistance (SMD -0.76; 95% CI,
−1.15, –0.36; P b 0.001) and hemoglobin A1c (SMD –1.22; 95% CI, −2.01, –0.44; P = 0.002), triglycerides
(SMD –0.58; 95% CI,−1.00,−0.16; P=0.006), total- (SMD –0.64; 95% CI,−1.01,−0.27; P=0.001), low density
lipoprotein-cholesterol (SMD –0.44; 95% CI,−0.76,−0.11; P= 0.008). We found no detrimental effect of ALA
supplementation on high density lipoprotein-cholesterol (HDL-cholesterol) levels (SMD 0.57; 95% CI,−0.14,
1.29; P= 0.11).
Conclusions: Overall, the current meta-analysis demonstrated that ALA administration may lead to an improve-
ment in glucose homeostasis parameters and lipid proﬁles except HDL-cholesterol levels.
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There are multiple primary and secondary causes of metabolic dis-
turbances related to metabolic syndrome (MetS) including impaired
glucose tolerance and hypertriglyceridemia, such as genetics, lifestyle
and diet especially obesity and reduced physical activity [1,2]. Previous
studies have reported that MetS is linked to a 2-fold increased risk of
cardiovascular disease (CVD) and a 5-fold increased risk of type 2 diabe-
tes mellitus (T2DM) over the next 5 to 10 years [3]. In addition, dyslip-
idemia [(hypertriglyceridemia, increased levels of total- and low
density lipoprotein-cholesterol (LDL-cholesterol) and decreased levels
of high density lipoprotein-cholesterol (HDL-cholesterol) is often corre-
latedwith insulin resistance, chronic diseases [4,5], and increased risk of
atherosclerotic events [6].
Common treatments for managing markers of insulin metabolism
and lipid proﬁles in patients with metabolic diseases include lifestyle
changes such as weight loss through an energy-restricted diet together
with increased energy expenditure throughphysical activity, various di-
etary patterns, and the appropriate use of pharmacological agents to re-
duction the speciﬁc risk factors [7,8]. To increase compliance and
adherence of patients withmetabolic diseases to lifestyle changes, com-
plementary therapies including antioxidants supplementation can be
useful [9]. Existing evidence has documented the beneﬁcial effects of
several antioxidants supplements including phenolic compounds [10],
some vitamins and minerals [9,11,12] on complications related to met-
abolic disorders. Investigations on antidiabetic and antilipidemic char-
acteristic of antioxidants have demonstrated that they can inhibit the
expression of cyclooxygenase-2 and P-selectin [13] and stimulate the
peroxisome proliferator-activated receptor gamma transduction path-
way [14]. Despite reported antidiabetic and antilipidemic characteristics
of alpha-lipoic acid (ALA) in some clinical trials [15–17], several studies
did shownopositive effects of ALA on glycemic control and lipid proﬁles
[18,19]. In addition, two previous meta-analyses studies have reported
the beneﬁcial effects of ALA supplementation on weight loss and body
mass index, and inﬂammatory markers [20,21]. Therefore, ALA supple-
mentation to promote glycemic status and lipid fractions remains con-
troversial. Discrepancies in ﬁndings might be the result of differences
in study design, characteristics of study populations, dosage of ALA
used and duration of the studies.
Despite several randomized controlled trials (RCTs), we are aware of
no systematic review and meta-analysis of RCTs about the effect of ALA
supplementation on glycemic control and lipid proﬁles among patients
with metabolic diseases. This meta-analysis was performed to summa-
rize the available evidence of RCTs to establish the effect of ALA supple-
mentation on glycemic control and lipid proﬁles among patients with
metabolic diseases.2. Methods
2.1. Search Strategy and Selection Studies
The design, implementation, analysis, and reporting of this study
were conducted in accordance with Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) guideline. We per-
formed a search of Cochrane Library, EMBASE, MEDLINE, and Web of
Science databases for relevant RCTs studies published till October
2017. Databases (International Standard Randomized Controlled Trial
Number Register and Meta-register for RCTs) were searched forongoing trials. RCTs retrieved that examined the association between
ALA supplementation on glycemic control and lipid proﬁles using the
following MeSH and text keywords: patients [“metabolic disease” OR
“MetS” OR “diabetes” OR “T2DM” OR “overweight” OR “obese” OR “ges-
tational diabetes mellitus (GDM)” OR “polycystic ovary syndrome
(PCOS)”], intervention (“ALA” OR “α-lipoic acid” AND “supplementa-
tion”OR “intake”), and outcomes [“triglycerides (TG) “OR “total-choles-
terol (TC)” OR “LDL-cholesterol” OR “LDL-C" OR “HDL-cholesterol” OR
“HDL-C" OR “fasting plasma glucose (FPG)”OR “insulin”OR “homeosta-
sismodel assessment of insulin resistance (HOMA-IR)”OR “hemoglobin
A1c" OR “HbA1c”]. The references list of all known related studies were
reviewed to identify additional potential publications that was not cap-
tured based on the electronic searches.We applied studies published in
the English language without time restrictions for publication. Two in-
dependent authors (RT,MA) have selected studies in two-stage process.
In the ﬁrst stage, authors observed the titles and/or abstracted to ﬁnd
trials had potential eligibility. In the second stage, the full texts of related
trials were retrieved for detailed evaluation. In the event of a discrepan-
cy, it is resolved by consensus or discussion with a third author (ZA).
Studies were selected according to the following criteria: 1) original
studies, 2) humanRCTs in design, 3) the target populationwere patients
with metabolic diseases, 4) intervention group received of ALA supple-
ments or ALA plus other nutrients, whereas the control group received
placebo, and 5) the trials reported mean changes of glycemic control
and/or lipid proﬁles with standard deviation (SD) for the intervention
and control groups.2.2. Data Extraction and Quality Assessment
Two authors (VO and MA) independently extracted, as well as two
authors assessed (RT and MA) the quality of all relevant studies when
therewas disagreement, it was resolved by discussionwith third author
(ZA) or until consensus was reached. The Cochrane Collaboration risk of
bias tool used to assess the quality of the included RCTs based on infor-
mation on the following domains: randomization generation, allocation
concealment, blinding of participants and outcome assessment, incom-
plete outcome data, and selective outcome reporting, and other sources
of bias.2.3. Data Analysis
All statistical analyses were performed using STATA version 12.0
(Stata Corp, College Station, TX) and RevMan V.5.3 software (Cochrane
Collaboration, Oxford, UK). Heterogeneity between included primary
studies was estimated using Cochran's Q test and I-square statistic. I-
square higher than 50% with p b 0.05 represented signiﬁcant heteroge-
neity. This study estimated the standardized mean difference (SMD)
with 95% conﬁdence interval (CI) by inverse variance method and
Cohen statistics. Since the indications could effect on pooled SMD
were different between included studies, we used random-effects
models for meta-analysis. Subgroup analyses were performed to assess
the source of heterogeneity between studies heterogeneity. To explore
the contribution of a particular study to the overall mean difference
was performed sensitivity analysis. Egger's test and funnel plotwere ap-
plied to identify the presence of publication bias for the primary out-
come measure. The P-value of (2-tailed) b0.05 were considered as
statistically signiﬁcant.
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3.1. Search Results
Our initial search found 1012 potential citations. After screening ar-
ticles, 24 paperswere found to be eligible for ourmeta-analysis. The de-
tails of step by step study identiﬁcation and selectionwere illustrated in
Fig. 1. Fourteen studies were double-blind design, eight studies were
randomized, placebo-controlled trial, and two were RCT. Twelve trials
examined the effects of ALA on glycemic control and lipid proﬁles
among patients with T2DM [15,17,19,22–30] and the remaining studies
were among other metabolic diseases. Overall, nineteen trials have re-
ported changes in lipid proﬁles include triglycerides, total-, LDL- and
HDL-cholesterol, and twenty studies have reported changes in and glu-
cose metabolism including FPG, insulin, HOMA-IR, and HbA1c. The du-
ration of intervention among studies varied from 2 to 51 weeks. The
dosage of ALA supplements used was from 200 to 1800 (mg/day). Six
studies were conducted in China [18,22,23,29–31], ﬁve in ItalyArticles screened by title and 
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Fig. 1. Literature search and review ﬂ[27,32–35], two in Republic of Korea [28,36], Iran [15,37], and Spain
[16,38], and one in Brazil [19], Bosnia and Herzegovina [17], India [24],
Austria [26], USA [39], Thailand [25], and New Zealand [40]. Table 1
shows the details of the included study characteristics into meta-
analysis. The quality of included studies, which was explored using
the Cochrane Collaboration risk of bias tool by the judgments of author
are presented in Fig. 2. The ﬁndings of risk of bias assessment indicated
that three studies were rated at low risk of bias, 19 studies were at un-
clear risk of bias, and 2 studies were at high risk bias based on the judg-
ments of author.
3.2. The Effects of ALA Supplementation on Glucose Metabolism
ALA supplementation signiﬁcantly decreased FPG (SMD−0.54; 95%
CI,−0.89,−0.19; P= 0.003), insulin concentrations (SMD -1.01; 95%
CI, −1.70, −0.31; P = 0.006), HOMA-IR (SMD -0.76; 95% CI, −1.15,
−0.36; P b 0.001) and HbA1c (SMD -1.22; 95% CI,−2.01,−0.44; P =
0.002) (Table 2& Fig. 3).le excluded (n=532) due to duplicate 
es, not randomized controlled trials, 
w and not human  
luded non-relevant articles (n=398) 
cles excluded (n=60): 
ot metabolic disease (n=29)  
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Table 1
Characteristics of included studies.
Authors (Ref) Publication
year
Sample size
(control/
intervention)
Country/population Intervention
(name and daily
dose)
Duration Presented data Age (control,
intervention)
Results (intervention
group)
Oliveira et al.
[19]
2011 26/26 Brazil/T2DM 600 mg ALA plus
other nutrients
4
months
TC, TG, LDL-C,
HDL-C, FPG, insulin,
HOMA-IR
62.51, 59.98,
range: 38–75
Decreased TC, LDL-C, TG, FPG,
insulin, HOMA-IR, and increased
HDL-C
Khabbazi et al.
[37]
2012 28/24 Iran/HD 600 mg ALA 8 weeks TC, TG, LDL-C,
HDL-C
54.04 ±
13.96, 53.83
± 13.29
Increased TC, TG, LDL-C, HDL-C
Capasso et al.
[35]
2013 78/77 Italy/Postmenopausal
women with MetS
200 mg ALA + 4
g inositol
6
months
TC, TG, HDL-C, FPG,
insulin, HOMA-IR
58.2 ± 5.6,
57.71 ± 7.9
Decreased TC, TG, FPG, insulin,
HOMA-IR, and increased HDL-C
Gianturco
et al. [34]
2012 46/52 Italy/NAFLD 400 mg ALA 12
months
TC, TG, LDL-C,
HDL-C, FPG, insulin,
HOMA-IR
61.0 ± 3.8,
60.0 ± 3.9
Decreased TC, TG, LDL-C, HDL-C,
insulin, HOMA-IR, and increased
FPG
Cianci et al.
[33]
2015 20/26 Italy/PCOS 600mg ALA+ 1 g
DCI
180 days TC, TG, HDL-C,
insulin, HOMA-IR
23.8 ± 2.5,
Range: 16–32
Decreased TC, TG, insulin,
HOMA-IR and increased HDL-C
McMackin
et al. [39]
2007 21/15 USA/CAD 400 mg ALA + 1
g
acetyl-L-carnitine
8 weeks TG, TC, LDL-C,
HDL-C, insulin, FPG
64.0 ± 7.0,
62.0 ± 5.0
Decreased TC, TG, HDL-C, FPG
and increased LDL-C, insulin
Li et al. [18] 2017 83/87 China/Obese or over-
weight patients
1200 mg ALA 8 weeks TG, TC, HDL-C a43[38–47],
44[39–47]
Decreased TG and TC, increased
HDL-C
Gianturco
et al. [27]
2009 7/7 Italy/T2DM 400 mg ALA 4 weeks TG, TC, LDL-C,
HDL-C
58.0 ± 16.0,
61.0 ± 7.0
Decreased TC, TG, LDL-C, and
increased HDL-C
Okanović et al.
[17]
2015 30/30 Bosnia and
Herzegovina/Obese pa-
tients with T2DM
600 mg ALA +
metformin
20
weeks
TG, FPG 61.13 ± 1.34,
62.97 ± 1.46
Decreased TG and FPG
Zhao et al. [22] 2014 44/46 China/T2DM 600 mg ALA (IV) 3 weeks TC, TG, LDL-C, FPG,
HOMA-IR, Hb1Ac
71.6, range:
60–92
Decreased TC, TG, LDL-C, FPG,
HOMA-IR, Hb1Ac
Zhang et al.
[30]
2011 9/13 China/Obese patients
with impaired glucose
tolerance
600 mg ALA (IV) 2 weeks TC, TG, LDL-C,
HDL-C, FPG, insulin
52.6 ± 6.2,
52.5 ± 8.2
Decreased TC LDL-C, FPG,
insulin and increased HDL-C
Udupa et al.
[24]
2012 21/23 India/T2DM 300 mg ALA (IV) 90 days TC, FPG, insulin 53.8 ± 2.1,
53.5 ± 1.4
Decreased TC, FPG, insulin
Huang et al.
[23]
2013 40/40 China/T2DM 600 mg ALA (IV)
for 2 weeks +
CSII
3
months
TC, LDL-C, HDL-C,
FPG, insulin, HbA1c
50.8 ± 9.7,
49.6 ± 10.5
Decreased TC, LDL-C, FPG,
insulin, HbA1c, and increased
HDL-C
Rago et al. [32] 2015 22/22 Italy/PCOS 800 mg ALA + 2
g MI
3
months
TC, TG, LDL-C,
HDL-C, FPG, insulin
36.3 ± 2.8,
37.1 ± 2.7
Decreased TC, TG, LDL-C, FPG,
insulin and increased HDL-C
Sun et al. [31] 2012 28/28 China/ARMD 600 mg ALA 3
months
TC, TG, LDL-C,
HDL-C
64.47 ± 8.13,
65.78 ± 7.93
Decreased TC, LDL-C, and
increased TG, HDL-C
Chang et al.
[28]
2007 25/25 Korea/Diabetic HD 600 mg ALA 3
months
TC 66.0 ± 7.0,
63.0 ± 6.0
Decreased TC
Heinisch et al.
[26]
2010 15/15 Austria/T2DM 600 mg ALA 3 weeks TC, TG, LDL-C,
HDL-C, HbA1c
56.0 ± 6.0,
55.0 ± 8.0
Decreased TC, TG, LDL-C, HDL-C,
HbA1c
Xiang et al.
[29]
2011 30/30 China/Patients with im-
paired fasting glucose
600 mg ALA 3 weeks TC, TG, LDL-C,
HDL-C, FPG
58.0 ± 9.0,
58.0 ± 10.0
Decreased TG, LDL-C, FPG and
increased TC, HDL-C
Koh et al. [36] 2011 73/82 Republic of Korea/obese
patients
1800 mg ALA 20
weeks
TG, HDL-C, HbA1c,
FPG
40.7 ± 12.04,
41.4 ± 10.95
Decreased TG, HDL-C, HbA1c,
and increased FPG
Ansar et al.
[15]
2011 28/29 Iran/T2DM 300 mg ALA 8 weeks FPG, HOMA-IR 51.82 ± 8.25,
49 ± 9.07
Decreased FPG, HOMA-IR
Huerta(I) et al.
[16]
2015 22/17 Spain/Overweight and
Obese Women
300 mg ALA +
1.3 g EPA
10
weeks
Insulin, HOMA-IR 39.0 ± 8.0,
39.0 ± 7.0
Decreased insulin, and
HOMA-IR
Huerta(II)
et al. [38]
2015 21/17 Spain/Overweight and
Obese Women
300 mg ALA +
1.3 g EPA
10
weeks
FPG 38.5 ± 7.1,
range: 20–45
Decreased
FPG
Porasuphatana
et al. [25]
2011 8/7 Thailand/T2DM 1200 mg ALA 6
months
HbA1c 42.9 ± 7.12,
47.7 ± 5.76
Decreased HbA1c
Manning et al.
[40]
2012 40/34 New Zealand/MetS 600 mg ALA 12
months
FPG 57.0 ± 9.0,
55.0 ± 10.0
No effect on FPG
ALA, Alpha-lipoic acid; CSII, Short-term continuous subcutaneous insulin infusion; DCI, D-chiro-inositol; EPA, eicosapentaenoic acid; HDL-C, high density lipoprotein-cholesterol; LDL-C,
low density lipoprotein-cholesterol; HD, heart disease; MetS, metabolic syndrome; NAFLD, Nonalcoholic fatty liver disease; CAD, coronary artery disease; PCOS, polycystic ovary syn-
drome; NIDDM, non-insulin-dependent diabetes mellitus; ARMD, Age-related macular degeneration; TC, total cholesterol; TG, triglycerides; T2DM, type 2 diabetes mellitus; FPG, fasting
plasma glucose; HbA1c, hemoglobin A1c; HOMA-IR, homeostatic model assessment for insulin resistance.
a Median [IQR].
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the intervention are presented in Table 3.
Sensitivity analysis was conducted and the results remained consis-
tent with the pooled effect (Fig. 5).
Egger's regression tests indicated no signiﬁcant publication bias for
meta-analyses assessing the effects of ALA on FPG (B = −2.25, P =
0.42), insulin (B =−1.33, P = 0.75), HOMA-IR (B = 3.06, P = 0.75),
and HbA1c (B =−1.37, P= 0.75).3.3. The Effects of ALA Supplementation on Lipid Proﬁles
The effects of ALA supplementation on lipid proﬁles were shown in
Fig. 4. The results showed that ALA supplementation among patients
with metabolic diseases signiﬁcantly decreased triglycerides (SMD
-0.58; 95% CI, −1.00, −0.16; P = 0.006), total- (SMD –0.64; 95% CI,
−1.01, −0.27; P = 0.001) and LDL-cholesterol (SMD -0.44; 95% CI,
−0.76, −0.11; P = 0.008). We found no detrimental effect of ALA
Fig. 2. The methodological quality of included studies (risk of bias).
60 M. Akbari et al. / Metabolism Clinical and Experimental 87 (2018) 56–69supplementation on HDL-cholesterol levels (SMD 0.57; 95% CI,−0.14,
1.29; P= 0.11).
Table 2 shows all meta-analyses between study population in in-
cluded trials by pre and post changed in intervention and control
groups. Because of existence heterogeneity, we conducted several sub-
group analyses by suspected variables including type of diseases, dosage
of ALA used, the duration of study, geographic area, and the type of in-
tervention. The effects were different in some of speciﬁc groups of stud-
ies which the details of subgroup analyses were shown in Table 3.
Sensitivity analysis was performed and the results for triglycerides,
total-, and LDL-cholesterol remained consistent with pooled effect
size. But the pooled SMD for HDL-cholesterol found signiﬁcant differ-
ence between the pre-sensitivity pooled SMD (0.57; 95% CI, −0.14,
1.29) and post-sensitivity pooled SMD (0.76; 95% CI, 0.10, 1.42) after ex-
cluding Gianturco et al. study (Fig. 5).
Egger's regression tests indicated no signiﬁcant publication bias for
meta-analyses assessing the effects of ALA on triglycerides (B =
−3.64, P = 0.12), total- (B = −2.17, P = 0.35), HDL-cholesterol (B
= 3.03, P = 0.49). Because there was evidence of publication bias on
LDL-cholesterol (B = −4.38, P = 0.01), we used non parametricTable 2
Estimation of the standardized difference means of related indictors with CI 95% between the
Parameter Number of study
Fasting glucose Intervention group (after vs. before) 15
Placebo group (after vs. before) 15
Change intervention group vs. placebo group 15
Insulin Intervention group (after vs. before) 7
Placebo group (after vs. before) 7
Change intervention group vs. placebo group 8
HOMA-IR Intervention group (after vs. before) 6
Placebo group (after vs. before) 6
Change intervention group vs. placebo group 7
HbA1c Intervention group (after vs. before) 5
Placebo group (after vs. before) 5
Change intervention group vs. placebo group 6
Triglycerides Intervention group (after vs. before) 14
Placebo group (after vs. before) 14
Change intervention group vs. placebo group 16
Total cholesterol Intervention group (after vs. before) 16
Placebo group (after vs. before) 16
Change intervention group vs. placebo group 17
LDL-cholesterol Intervention group (after vs. before) 12
Placebo group (after vs. before) 12
Change intervention group vs. placebo group 12
HDL-cholesterol Intervention group (after vs. before) 13
Placebo group (after vs. before) 13
Change intervention group vs. placebo group 15method (Duval and Tweedie) to estimate the results of censored stud-
ies. The meta-analysis based on these studies showed that summary ef-
fect size on LDL-cholesterol was not signiﬁcant changed between before
included censored studies into meta-analysis (SMD -0.44; 95% CI,
−0.76,−0.11) and after (SMD -0.44; 95% CI,−0.76,−0.11).
4. Discussion
This systematic review and meta-analysis assessed the effect of ALA
supplementation on glycemic control and lipid proﬁles in patients with
metabolic diseases. This meta-analysis showed that ALA administration
may lead to an improvement in glucose homeostasis parameters and
lipid proﬁles except HDL-cholesterol levels. It must be kept in mind
that few metabolic diseases especially diabetes mellitus may lead to
neurological complications which its management focuses on glycemic
control, multifactorial cardiovascular risk intervention, and
pathogenesis-oriented therapy [21]. Existing evidence suggests that
ALA increases glutathione levels, prevents lipid peroxidation, enhances
the activity of antioxidant enzymes and increases blood ﬂow and glu-
cose uptake diabetic neuropathy [41,42]. Moreover, ALA may reduceintervention and placebo groups.
Standardized
mean difference
CI 95% Heterogeneity
I-squared (%) Q P-value
−0.84 −1.39,−0.28 94.3 246.92 b0.001
−0.53 −1.05,−0.01 93.5 216.15 b0.001
−0.54 −0.89,−0.19 86.9 106.69 b0.001
−0.50 −0.88,−0.12 74.2 23.23 0.001
−0.11 −0.29, 0.08 0.0 1.47 0.96
−1.01 −1.70,−0.31 91.9 86.74 b0.001
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Fig. 3. A–D. Meta-analysis glycemic control standardizedmean differences estimates for (A) fasting plasma glucose, (B) for insulin, (C) for HOMA-IR, and (D) for HbA1c in alpha-lipoic acid
supplements and placebo groups (CI = 95%).
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Table 3
The effects of alpha-lipoic acid supplementation on glycemic control and lipid proﬁles based on subgroup analysis.
Parameter Number of
SMD included
Subgroups Pooled OR
(random effect)
95% CI I-squared (%) Overall
I-squared (%)
Triglycerides Type of diseases 7 T2DM −1.46 −2.63,−0.28 95.0 90.9
9 Non-T2DM −0.22 −0.53, 0.10 78.9
Dosage of ALA (mg/day) 4 b600 −0.25 −0.97, 0.47 86.5
9 =600 −1.12 −1.93,−0.31 93.6
3 N600 −0.03 −0.24, 0.18 11.3
Duration of study (week) 5 b8 −0.54 −1.27, 0.18 82.1
5 8–12 0.02 −0.18, 0.22 0.00
6 N12 −1.36 −2.30,−0.43 95.8
Geographic area 8 American or European −0.99 −1.80,−0.17 94.2
8 Other countries −0.30 −0.68, 0.08 80.1
Type of intervention 11 ALA −0.21 −0.51, 0.08 73.2
5 ALA + other nutrients −1.79 −3.09,−0.49 96.2
Total cholesterol Type of diseases 9 T2DM −1.03 −1.80,−0.27 92.3 88.1
8 Non-T2DM −0.30 −0.56,−0.03 63.5
Dosage of ALA (mg/day) 5 b600 −0.73 −1.17,−0.29 68.4
10 =600 −0.72 −1.37,−0.06 92.0
2 N600 −0.28 −0.58, 0.02 23.9
Duration of study (week) 6 b8 −1.09 −2.28, 0.10 94.8
7 8–12 −0.37 −0.75, 0.00 73.5
4 N12 −0.55 −0.90,−0.20 57.5
Geographic area 7 American or European −0.39 −0.68,−0.10 54.4
10 Other countries −0.87 −1.50,−0.24 92.5
Type of intervention 12 ALA −0.84 −1.37,−0.31 90.7
5 ALA + other nutrients −0.26 −0.62, 0.10 65.0
LDL-cholesterol Type of diseases 7 T2DM −0.80 −1.32,−0.27 79.2 74.4
5 Non-T2DM −0.09 −0.40, 0.23 47.6
Dosage of ALA (mg/day) 3 b600 −0.61 −1.53, 0.31 79.4
8 =600 −0.47 −0.90,−0.04 78.6
1 N600 −0.22 −0.68, 0.23 0.00
Duration of study (week) 6 b8 −0.93 −1.56,−0.31 82.1
4 8–12 −0.11 −0.54, 0.33 60.0
2 N12 −0.11 −0.43, 0.21 0.00
Geographic area 5 American or European −0.33 −0.73, 0.08 59.0
7 Other countries −0.51 −1.01,−0.01 81.6
Type of intervention 9 ALA −0.59 −1.04,−0.14 80.6
3 ALA + other nutrients −0.15 −0.43, 0.14 0.00
HDL-cholesterol Type of diseases 6 T2DM 0.42 −0.35, 1.19 87.0 96.4
9 Non-T2DM 0.58 −0.45, 1.60 97.6
Dosage of ALA (mg/day) 4 b600 0.57 −1.38, 2.51 97.7
8 =600 0.18 −0.29, 0.66 81.3
3 N600 1.68 −0.82, 4.17 99.0
Duration of study (week) 5 b8 0.70 −0.23, 1.63 88.1
5 8–12 1.04 −0.65, 2.74 97.9
5 N12 −0.12 −1.23, 0.99 96.9
Geographic area 7 American or European 0.38 −0.65, 1.41 95.9
8 Other countries 0.73 −0.34, 1.81 97.1
Type of intervention 10 ALA 0.71 −0.40, 1.81 97.4
5 ALA + other nutrients 0.39 −0.32, 1.10 90.8
Fasting glucose Type of diseases 8 T2DM −0.82 −1.39,−0.26 87.8 86.9
7 Non-T2DM −0.25 −0.69, 0.20 86.0
Dosage of ALA (mg/day) 6 b600 −0.58 −1.36, 0.21 92.7
7 =600 −0.59 −1.17,−0.00 85.8
2 N600 −0.36 −0.80, 0.09 61.5
Duration of study (week) 4 b8 −0.79 −1.71, 0.13 91.0
5 8–12 −0.70 −1.41, 0.02 85.9
6 N12 −0.29 −0.78, 0.20 88.0
Geographic area 7 American or European −0.16 −0.63, 0.30 84.6
8 Other countries −0.88 −1.37,−0.38 86.9
Type of intervention 9 ALA −0.77 −1.31,−0.23 90.4
6 ALA + other nutrients −0.23 −0.62, 0.16 74.7
Insulin Type of diseases 2 T2DM −1.52 −4.18,1.14 93.5 91.9
6 Non-T2DM −0.89 −1.69,−0.10 92.9
Dosage of ALA (mg/day) 4 b600 −0.50 −1.47, 0.47 93.6
3 =600 −1.99 −4.05, 0.06 94.4
1 N600 −0.63 −1.10,−0.17 0.00
Duration of study (week) 1 b8 −2.94 −4.18,−1.69 0.00
3 8–12 −0.13 −0.80, 0.54 74.4
4 N12 −1.31 −2.31,−0.31 93.9
Geographic area 7 American or European −0.80 −1.50,−0.09 92.1
1 Other countries −2.94 −4.18,−1.69 0.00
Type of intervention 3 ALA −1.01 −2.03, 0.01 87.2
5 ALA + other nutrients −0.98 −1.99, 0.02 93.8
HOMA-IR Type of diseases 3 T2DM −0.60 −1.05,−0.15 58.1 78.1
(continued on next page)
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Table 3 (continued)
Parameter Number of
SMD included
Subgroups Pooled OR
(random effect)
95% CI I-squared (%) Overall
I-squared (%)
4 Non-T2DM −0.87 −1.47,−0.27 83.7
Dosage of ALA (mg/day) 4 b600 −0.85 −1.42,−0.27 83.4
3 =600 −0.62 −1.11,−0.12 62.2
– N600 – – –
Duration of study (week) 1 b8 −0.47 −0.89,−0.05 0.00
2 8–12 −0.68 −1.52, 0.17 75.1
4 N12 −0.87 −1.46,−0.27 84.6
Geographic area 5 American or European −0.75 −1.29,−0.21 83.1
2 Other countries −0.75 −1.36,−0.15 67.1
Type of intervention 4 ALA −0.58 −0.87,−0.26 38.2
3 ALA + other nutrients −1.00 −1.73,−0.27 82.0
HbA1c Type of diseases 5 T2DM −1.27 −2.83,−0.15 92.9 91.1
1 Non-T2DM −1.12 −1.46,−0.78 0.00
Dosage of ALA (mg/day) 1 b600 −1.79 −2.49,−1.08 0.00
3 =600 −0.80 −2.38, 0.78 95.8
2 N600 −1.57 −2.74,−0.39 67.2
Duration of study (week) 3 b8 −0.80 −2.38, 0.78 95.8
1 8–12 −1.79 −2.49,−1.08 0.00
2 N12 −1.57 −2.74,−0.39 67.2
Geographic area – American or European – – –
6 Other countries −1.22 −2.01,−0.44 91.1
Type of intervention 5 ALA −1.41 −2.34,−0.48 90.9
1 ALA + other nutrients −0.41 −0.85, 0.03 0.00
64 M. Akbari et al. / Metabolism Clinical and Experimental 87 (2018) 56–69complications related to diabetic neuropathy through modulating deﬁ-
cits of neuropeptides including Neuropeptide Y and substance P in the
spinal cord [43] and suppressing the activation of nuclear factor-κB in
peripheral nerves [44].
Subjects with metabolic diseases are susceptible to increased risk of
CVD, T2DM, and all-cause mortality [3]. The current meta-analysis of
RCTs documented that ALA supplementation to populationswithmeta-
bolic diseases resulted in a signiﬁcant decrease in fasting glucose, insu-
lin, HOMA-IR and HbA1c. Few studies have evaluated the beneﬁcial
effects of antioxidants supplementation on glycemic control in patients
with metabolic diseases. In a meta-analysis study, we have previously
showed that selenium supplementation to populations with metabolic
diseaseswas useful in improving insulin concentrations and insulin sen-
sitivity, but did not affect fasting glucose and HOMA-IR [9]. In addition,
in a systematic study conducted by Cruz et al. [11], zinc supplementa-
tion improved insulin resistance in obese subjects of both sexes. In an-
other meta-analysis study, magnesium supplementation signiﬁcantly
improved glucose parameters in populationswith diabetes and also im-
proved insulin-sensitivity parameters in those at high risk of diabetes
[45]. Lifestyle can play an important function in treatment of metabolic
disorders. However, some clinical trials did not point to the mainte-
nance of usual dietary intake and physical activity levels through the
treatment, andmost studies did not adjust results for these parameters.
Therefore, the effects of lifestyle and other confounding variables are
not clear. Several mechanisms have been proposed to mediate the
insulin-sensitizing actions of ALA, such as the improvement of glycemic
control through the preservation of beta-cell function [46]. In addition,
it has been suggested that ALA inhibits the progress of diabetes in
diabetes-prone obese rats by decreasing triglycerides accumulation in
non-adipose tissues such as muscle, pancreatic beta-cells, and liver
[47]. On the other hand, few of these beneﬁcial effects on insulin resis-
tance have been proposed to be mediated by the modulation of adeno-
sinemonophosphate-activated protein kinase (AMPK) [47]. Thus, it has
been documented that ALA decreases insulin resistance by activating
AMPK in skeletal muscle [48] and beta-cells [49].
Our meta-analysis demonstrated that ALA supplementation to sub-
jects with metabolic diseases was effective in reducing triglycerides,
total- and LDL-cholesterol levels, but did not affect HDL-cholesterol
levels. Existing evidence from animal models suggests a lipid-lowering
response to ALA administration. For example, rats fed a high fat diet
with 0.5% ALA shown a decrease in total lipids (21.3%), triglycerides
(31.9%), total- (20.1%), LDL-cholesterol (41.1%), and free fatty acids(33%) compared with the control group [50]. In another study, which
evaluated the effects of different dosages of ALA (0, 1, 2.5, and 5 g/kg)
in Sprague-Dawley rats on lipid proﬁles demonstrated reductions in tri-
glycerides (68.5%), total cholesterol (25.8%), and non-esteriﬁed fatty
acids (45%) [51]. In addition, limited evidence from human studies sug-
gests that ALA may have lipid-lowering effects [52]. A short-term
(2 weeks) ALA supplementation at a dosage of 600 mg/day to obese
populations with impaired glucose tolerance were effective in reducing
free fatty acids, triglycerides, total-, LDL-, oxidized LDL-, and VLDL-
cholesterol concentrations [30]. Masharani et al. [53] demonstrated a
signiﬁcant reduction in triglycerides (28%) and larger, more buoyant
LDL-particles in six leanwomenwith PCOS following the supplementa-
tion of 600 mg ALA twice daily for 6 weeks. Furthermore, a signiﬁcant
reduction in total cholesterol of 8% and a tendency toward lower LDL-
and higher HDL-cholesterol following 12 weeks of ALA supplementa-
tion at a dosage of 1200mg/day to overweight/obese schizophrenic pa-
tients was observed [54]. Conversely, few human studies have reported
no detrimental effect of ALA supplementation on lipid proﬁles. For ex-
ample, diabetic end-stage renal disease (ESRD) populations on hemodi-
alysis taking 600 mg/day ALA for 12 weeks exhibited no signiﬁcant
changes in total-cholesterol or oxidized-LDL compared with the control
group [28]. In another similar study, Khabbazi et al. [37] did not observe
any change in lipid fractions following the supplementation of 600 mg
ALA/day for 8 weeks in patients with ESRD on hemodialysis compared
with the placebo. Koh et al. [55] demonstrated even after weight loss,
no signiﬁcant change total-, HDL-cholesterol, and triglycerides was re-
ported in obese populations randomized to placebo, 1200 or
1800 mg/day of ALA supplements. Increased AMPK activity following
the intake of ALA in peripheral tissues including skeletal muscle has
been shown to directly inhibit fatty acid synthesis, while concomitantly
elevating in β-oxidation of fatty acids [51,56]. In addition, some studies
document that the expression of the two rate-limiting enzymes in fatty
acid synthesis, acetyl-CoA carboxylase and fatty acid synthase, are de-
creased in response to ALA administration [56,57]. On the other hand,
reductions in lipid proﬁles following the supplementation of ALA may
be secondary to decreases in insulin concentrations and insulin resis-
tance. In addition, previous studies have demonstrated that
nutraceuticals play a peculiar role in ameliorating human dyslipidaemia
[58,59], which in turn effectively able to decrease the burden of the ath-
erosclerosis process and the progress of CVD [60]. Nutraceuticals may
improve lipid proﬁles through upregulating hepatic LDL receptors, re-
ducing intestinal absorption of cholesterol [61], blocking carbohydrate
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Fig. 4. A–D. Meta-analysis lipid proﬁles standardized mean differences estimates for (A) triglycerides, (B) for total-, (C) for LDL-, and (D) for HDL-cholesterol in alpha-lipoic acid
supplements and placebo groups (CI = 95%).
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67M. Akbari et al. / Metabolism Clinical and Experimental 87 (2018) 56–69digestion and glucose absorption in the gut, decreasing glucose release
from liver and activating insulin receptors [62].
Overall, the current meta-analysis demonstrated that ALA adminis-
trationmay lead to an improvement in glucose homeostasis parameters
and lipid proﬁles except HDL-cholesterol levels. The ﬁndings of this
meta-analysis may have a high impact in the ﬁeld of nutraceuticals
and therapy for metabolic diseases. Additional prospective studies in-
vestigating the effect of ALA supplementation on glucose homeostasis
parameters and lipid proﬁles inMetS are necessary. -1.11  -0.58 -1.00  -0.16  -0.01
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